recombinant mutant human tumor necrosis factor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for recombinant mutant human tumor necrosis factor, covering 2026-02-09 to 2026-02-09. Get the full timeline:
Most recent: Clinical Trial Update: Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy [Phase 1, Phase 2]